Scholarlink

<p>Follow-up care after curative treatment for breast cancer has remained largely unchanged for decades. Routine screening for asymptomatic distant metastases is not recommended, meaning such relapses are often detected incidentally or after patients experience symptoms, leading to palliative intent treatment. In light of modern diagnostic and therapeutic options, this approach appears outdated. Liquid biopsy, especially the detection of circulating tumor DNA (ctDNA), offers a&#xa0;promising method to identify minimal residual disease (MRD) early, before clinical or radiological signs for (distant) recurrence appear. This could enable earlier intervention with effective therapies. However, prospective studies to support a&#xa0;change in follow-up care are still lacking. The currently recruiting Standard Surveillance versus Intensive Surveillance in Early Breast Cancer (SURVIVE) study aims to close this gap.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Von der Routine zur Präzisionsmedizin – die Nachsorge beim frühen Mammakarzinom auf dem Prüfstand

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月21日

查看全文
  • Sophia T. Huesmann,
  • Henning Schäffler,
  • Kerstin Pfister,
  • Tatjana Braun,
  • Angelina Fink,
  • Sabine Heublein,
  • Brigitte Rack,
  • Wolfgang Janni

摘要

Follow-up care after curative treatment for breast cancer has remained largely unchanged for decades. Routine screening for asymptomatic distant metastases is not recommended, meaning such relapses are often detected incidentally or after patients experience symptoms, leading to palliative intent treatment. In light of modern diagnostic and therapeutic options, this approach appears outdated. Liquid biopsy, especially the detection of circulating tumor DNA (ctDNA), offers a promising method to identify minimal residual disease (MRD) early, before clinical or radiological signs for (distant) recurrence appear. This could enable earlier intervention with effective therapies. However, prospective studies to support a change in follow-up care are still lacking. The currently recruiting Standard Surveillance versus Intensive Surveillance in Early Breast Cancer (SURVIVE) study aims to close this gap.